(KYMR) – StreetInsider.com Reports
-
Kymera Therapeutics (KYMR) Presents Preclinical Data for STAT6 and TYK2
-
Kymera Therapeutics (KYMR) PT Raised to $54 at Truist Securities
-
Kymera Therapeutics (KYMR) PT Raised to $56 at Piper Sandler
-
Kymera Therapeutics (KYMR) PT Raised to $34 at Morgan Stanley
-
Kymera Therapeutics (KYMR) PT Raised to $31 at B.Riley
-
Kymera Therapeutics (KYMR) PT Raised to $47 at JPMorgan
-
Kymera Therapeutics (KYMR) PT Raised to $55 at Stifel
-
Kymera Therapeutics (KYMR) PT Lowered to $30 at H.C. Wainwright
-
Kymera Therapeutics (KYMR) PT Raised to $30 at Wells Fargo
-
Kymera Therapeutics (KYMR) Tops Q4 EPS by 15c
-
Wolfe Research begins coverage on biotech, names Alpine Immune Sciences as Top Pick
-
Wolfe Research Starts Kymera Therapeutics (KYMR) at Peerperform
-
Kymera Therapeutics (KYMR) PT Raised to $112 at Brookline Capital Markets
-
Kymera Therapeutics (KYMR) PT Raised to $33 at Morgan Stanley
-
Kymera Therapeutics (KYMR) Prices $275M Share and Warrant Offering at $25.25/sh
-
Kymera Therapeutics (KYMR) Announces Proposed $250M Share Offering
-
JPMorgan Upgrades Kymera Therapeutics (KYMR) to Overweight
-
BofA Securities Downgrades Kymera Therapeutics (KYMR) to Neutral, 'limited NT catalysts'
-
Kymera Therapeutics (KYMR) PT Raised to $103 at Brookline Capital Markets
-
Wells Fargo Downgrades Kymera Therapeutics (KYMR) to Equal Weight, 'Lack of Catalysts in 2024'
-
Kymera Therapeutics (KYMR) Presents Interim Results from STAT3 Degrader Phase 1 Trial
-
Kymera Therapeutics (KYMR) Announces Publication of Phase 1 Trial Results for KT-474
-
Kymera Therapeutics (KYMR) PT Lowered to $24 at Morgan Stanley
-
Kymera Therapeutics (KYMR) PT Lowered to $45 at BofA Securities
-
Kymera Therapeutics (KYMR) PT Lowered to $30 at H.C. Wainwright
-
Kymera Therapeutics (KYMR) PT Lowered to $41 at Truist Securities
-
Kymera Therapeutics (KYMR) PT Lowered to $38 at Piper Sandler
-
Kymera Therapeutics (KYMR) PT Lowered to $35 at Stifel
-
Kymera Therapeutics (KYMR) PT Lowered to $16 at B.Riley
-
Kymera Therapeutics (KYMR) Misses Q3 EPS by 26c
-
Kymera Therapeutics (KYMR) Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
-
Kymera Therapeutics (KYMR) Receives U.S. FDA Fast Track Designation for KT-333 for CTCL and R/R PTCL
-
Kymera Therapeutics (KYMR) PT Lowered to $37 at Morgan Stanley
-
Kymera Therapeutics (KYMR) PT Raised to $52 at Stifel
-
Kymera Therapeutics (KYMR) PT Raised to $37 at Credit Suisse
-
Kymera Therapeutics (KYMR) PT Lowered to $42 at JPMorgan
-
Kymera Therapeutics (KYMR) Misses Q2 EPS by 3c
-
Truist Securities Starts Kymera Therapeutics (KYMR) at Buy
-
Kymera Therapeutics' (KYMR) STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Trials
-
Kymera Therapeutics (KYMR) Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
-
Kymera Therapeutics (KYMR) Appoints Jeremy Chadwick as COO
-
Kymera Therapeutics (KYMR) Presents Clinical Data from the Phase 1 Trial on KT-474
-
Kymera Therapeutics (KYMR) PT Lowered to $39 at Morgan Stanley
-
Kymera Therapeutics (KYMR) PT Lowered to $36 at Credit Suisse
-
Raymond James Upgrades Kymera Therapeutics (KYMR) to Outperform, 'Improved Risk/Reward Setup'
-
Kymera Therapeutics (KYMR) PT Lowered to $53 at Stifel
-
Kymera Therapeutics (KYMR) PT Raised to $39 at Credit Suisse
-
Kymera Therapeutics (KYMR) Tops Q4 EPS by 3c
-
Kymera Therapeutics (KYMR) Shares Key 2023 Goals
-
Kymera Therapeutics (KYMR) PT Lowered to $65 at Guggenheim
Back to KYMR Stock Lookup